Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. A number of drug development programs are currently being conducted to evaluate our drug candidates in diseases such as bipolar disorder and Friedreich's ataxia.

We currently market recombinant Protein A, which partially funds the advancement of our product development pipeline while supporting our financial stability. In addition, we secured a source of revenue through the successful licensing of our patent covering the use of CTLA4-Ig, and receive royalties from Bristol-Myers Squibb based on their U.S. sales of Orencia® for rheumatoid arthritis.

Highlights

February 4, 2010
Repligen Reports Third Quarter Fiscal Year 2010 Financial Results more >

February 3, 2010
Repligen Receives Notice of Allowance for Recombinant Protein A Patent more >

February 1, 2010
Repligen to Present at the BIO CEO & Investor Conference
Monday, February 8th, 2:00 p.m. EST more >

January 29, 2010
Repligen Announces Conference Call of Third Quarter Fiscal Year 2010 Results Thursday, February 4th, 10:00 a.m. EST more >

January 28, 2010
Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A more >

December 15, 2009
Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program more >

December 9, 2009
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging more >

November 5, 2009
Repligen Reports Second Quarter Fiscal Year 2010 Financial Results more >

October 22, 2009
Repligen Licenses Potential Treatment for Spinal Muscular Atrophy
Conference Call Scheduled for Friday, October 23 at 8:30 EDT more >

October 22, 2009
Spinal Muscular Atrophy Program References more >

September 25, 2009
Repligen Announces Identification of Drug Target for Friedreich's Ataxia
Study Published in the September 25, 2009 Issue of Chemistry & Biology more >

Events

Q3 Fiscal Year 2010 Earnings Conference Call
Thursday, February 4th, 2010 at 10:00 A.M. EST
Dial-in: (800) 510-9836
International: (617) 614-3670
Passcode: 51466310
Listen to Webcast

BIO CEO and Investor Conference
Monday, February 8th, 2010 at 2:00 P.M. EST
Listen to Webcast